4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Short Bowel Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Short Bowel Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 23 ongoing clinical trials involving Short Bowel Syndrome
Of the 23 trials,8 trials are in Phase III
Furthermore, 6 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Short Bowel Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Short Bowel Syndrome, a gastrointestinal condition. The largest number of ongoing clinical trials for Short Bowel Syndrome is conducted in Europe. North America and Asia-Pacific are among some of the other prominent regions engaged in Short Bowel Syndrome-related drug trials.

Zealand Pharma AS: The leading ongoing Short Bowel Syndrome related clinical trial sponsor

Zealand Pharma AS is the top sponsor for Short Bowel Syndrome-related ongoing clinical trials.

VectivBio Holding AG, Shire Pharmaceuticals International UC, University of Ulm, and Mayo Clinic are among other notable clinical trial sponsors involved in Short Bowel Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Short Bowel Syndrome

Teduglutide (Revestive, Gattex), Somatropin (Zorbtive), and Cimetidine (Tagamet/Contracid) are among the key marketed drugs involving Short Bowel Syndrome.

Teduglutide (Revestive, Gattex) is a proprietary analog of naturally occurring human glucagon 2(GLP-2), belongs to gastrointestinal agent class. It functions via Glucagon Like Peptide 2 Receptor (GLP2R) Agonist mechanism of action. It is formulated as powder for solution for subcutaneous route of administration. Teduglutide is indicated for the treatment of short bowel syndrome in adults and pediatrics 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. It is under development for the treatment of short bowel syndrome in pediatrics. Teduglutide was first approved in 2012 and is marketed globally including the US, the UK, France, Canada, and Japan by several pharma giants including Takeda Pharmaceutical Co Ltd, and Shire Laboratories Inc.

Somatropin (Zorbtive) is a human growth hormone produced by recombinant DNA technology. It functions via Growth Hormone Receptor (Somatotropin Receptor or GHR) Agonist mechanism of action. It is formulated as injectable, powder for solution for subcutaneous route of administration. Zorbtive is indicated for the treatment of short bowel Syndrome in patients receiving specialized nutritional support. Somatropin was first approved in 2003 and is marketed in the US by EMD Serono Inc.

Explore the latest trends and actionable insights on the Short Bowel Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Short Bowel Syndrome Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store